Uquifa and chemistry SONEAS Acquisition Vivimed Labs Spain S.L, the parent of UQUIFA S.A, has signed definitive agreements to facilitate the acquisition of SONEAS, a Budapest (Hungary) headquartered CDMO company, focussed on the Innovator Pharmaceutical and Fine Chemical sectors. The business has been acquired from Lochlomond and Euroventures which are both based out of Hungary. SONEAS has for the year 2017, reported revenues of €12.2mn. The acquisition broadens UQUIFA´s market offering in the CDMO space by enhancing its ability to now undertake preclinical, phase I, II and III NCE project development. These projects can then also potentially feed into UQUIFA´s existing cGMP inspected and approved manufacturing facilities in Spain and Mexico, creating a high-value project pipeline. About SONEAS SONEAS, established in 1996, with a team strength of 144 people, is a Budapest, Hungary headquartered firm with business verticals focused on R+D and CMO, targeted at the Innovator Pharma and Fine Chemical sectors.In R+D, it is a professional chemical service provider with research and analytical labs across two operating sites in Budapest. It also has an 8,000 sq mtr facility which houses process R+D, kilo lab and a cGMP approved pilot plant facility which was commissioned in 2002. In CMO, it is operating on 65,000 m2 site and capable of providing starting materials, intermediates for pharma and non-pharma applications as well as other fine chemical products on a commercial scale. SONEAS existing customer base includes names like Chinoin, Ogeda, Eisai, Leo Pharma among others. For further information on SONEAS, visit www.soneas.com Who we are UQUIFA is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical industry globally. The Company has 3 manufacturing sites (2 in Spain and 1 in Mexico) with strict adherence to all regulatory norms. These sites operate under cGMP conditions and have been inspected and approved by leading global pharmaceutical companies and regulatory authorities, including the US FDA. Bidar in India manufactures KSM's. API Sites 3 locations in Spain and 1 in Mexico and +20 certificates of suitability gives us geographical spread with +40 Type II DMF's filed with the FDA and more than 150 active DMF's Worldwide Barcelona, Spain Main office Located in Passeig de Gràcia CEO central functions 50 administration and management personnel Sant Celoni, Spain High tech site with main R+D centre for APIs and CMO Total capacity of 155m3 FDA last inspection May'17 c-GMP, Korean FDA (2011), Jap-Cert, ANVISA Lliçà, Spain Total capacity 150m3 FDA last inspection Sept'15 c-GMP, Korean FDA (2011), Jap-Cert Cuernavaca, Mexico R+D centre for APIs and CMO Competitive manufacturing base Total capacity 200m3 FDA last inspection Sept'14 CGMP, ANVISA Our Mission, Our Vision, Our Values We strive to meet maximun quality standards, continuous improving development processes and respecting legislation and the environment. Corporate compliance UQUIFA believes one of the keys to sustainable success is to always act within the law by meeting all ethical principes in today's society. HomeCompany Company About us Senior Management Team Board of Directors API Sites Mission, Vision, Values Corporate compliance Corporate deck Uquifa Certificates Team and corporate structure CMO Corporate layout Technical details 25 years of molecules Address Uquifa - Barcelona C/ Mallorca 262, 3º Barcelona 08008 (España) +34 934 674 810 Use contact form Legal Privacy Notice Política de cookies Contact Us Full Name Email Message SUBMIT Uquifa Copyright © 2021 Uquifa. All Rights Reserved. Designed by.